Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

mimedx.com

Founded Year

2008

Stage

PIPE | IPO

Market Cap

0.31B

About Mimedx

MiMedx is a medical device company focused exclusively on the spine. The company develops SaluDisc, a patented total disc replacement technology for sufferers of chronic back pain.

Mimedx Headquarters Location

1775 West Oak Commons Ct. NE

Marietta, Georgia, 30062,

United States

770-651-9100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Mimedx Patents

Mimedx has filed 100 patents.

The 3 most popular patent topics include:

  • Stem cells
  • Developmental biology
  • Embryology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/21/2018

7/19/2022

Embryology, Developmental biology, Stem cells, Midwifery, Collagens

Grant

Application Date

5/21/2018

Grant Date

7/19/2022

Title

Related Topics

Embryology, Developmental biology, Stem cells, Midwifery, Collagens

Status

Grant

Latest Mimedx News

MiMedx Group Launches Axiofill

Sep 23, 2022

Charles Sternberg, Associate Editor09.23.22 MiMedx Group Inc., a transformational placental biologics company, has launched Axiofill, an Extracellular Matrix (ECM) Particulate product derived from human placental tissue. Axiofill is a human placental-derived particulate product available for Surgical Recovery procedures. It offers a competitive advantage over other xenograft, or animal-based, particulate products that undergo aggressive processing techniques to eliminate potential antigens. The existing market for xenograft products, including particulates, is estimated at $230 million. Axiofill provides a cost-effective human collagen scaffold that is conducive for use in large, complex wounds and those of irregular geometries. It may be applied directly as a dry particulate, or with the addition of saline, as a paste depending upon surgeon preference and clinical need. “The launch of Axiofill is particularly significant for MiMedx,” said Rohit Kashyap, Ph.D., MiMedx president, Wound Care & Surgical. “We have added another new product to our portfolio that is designed for the needs of the Surgical Recovery market, enhancing the value we provide to customers. As the first human placenta-derived ECM particulate, we believe that Axiofill offers a distinct advantage over other particulate products and provides impressive clinical utility for physicians treating complex surgical wounds. Importantly, we continue to execute on our customer needs-driven innovation roadmap and view Axiofill as a strong platform for future product innovation.”   “When considering treatment options to address significant tissue defects, physicians have a persistent need for a versatile product that conforms to a variety of complex wound configurations, whether an uneven surface defect or a deep, tunneling wound,” said Dr. Susan Hagen, general surgeon, Boulder, CO. “I believe Axiofill offers a safe, convenient and powerful tool that can be used in a wide variety of surgical applications.”   Axiofill is processed using a proprietary PURION technique that preserves the natural tissue microstructure. The resulting biocompatible scaffold retains key structural proteins, including type I and type IV collagen, laminin, and fibronectin. John Harper, Ph.D., MiMedx chief technology officer, senior vice president of Research and Product Development, added, “The scientific work we have done to characterize Axiofill highlights its role as a provisional scaffold that supports key regenerative processes, including cellular infiltration and neovascularization needed for the generation of site-appropriate functional tissue. MiMedx remains dedicated to developing novel products that address areas of unmet clinical need.” Related News MiMedx Group Inc. also recently launched Amnioeffect , a tri-layer PURION processed human tissue allograft consisting of the amnion, intermediate and chorion membrane layers of the placenta.

Mimedx Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Mimedx Rank

  • When was Mimedx founded?

    Mimedx was founded in 2008.

  • Where is Mimedx's headquarters?

    Mimedx's headquarters is located at 1775 West Oak Commons Ct. NE, Marietta.

  • What is Mimedx's latest funding round?

    Mimedx's latest funding round is PIPE.

  • Who are the investors of Mimedx?

    Investors of Mimedx include EW Healthcare Partners, Hayfin Capital Management, Clayton Associates and The Trelys Funds.

  • Who are Mimedx's competitors?

    Competitors of Mimedx include SynCardia Systems, Pinnacle Transplant Technologies, SynergEyes, Rheonix, Magneceutical Health and 12 more.

You May Also Like

Minimus Spine Logo
Minimus Spine

Minimus Spine is developing ozone injection technology specifically for spinal applications. The company has improved upon the existing technology through a system that creates ozone, and measures its concentration, within in a sterile, syringe-cartridge. This has advantages in terms of sterility and dose assurance, as well as material compatibility, which are vital to the advancement of this technique.

C
Cardiola

Cardiola have designed a patented device, the m.pulse device designed to treat chronic heart failure (CHF), non-surgically, in a patient's home.

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

G
Gentis

Gentis is a developer of minimally invasive, biomaterials-based products intended to treat the early-stage degeneration of the spine, which causes back pain. The company's first patented product, DiscCell, is a breakthrough injectable biomaterial that augments or replaces the diseased nucleus pulposus of the spinal disc.

S
SpineForm

SpineForm is developing a less invasive spinal deformity surgical treatment. SpineForm's HemiBridge is a spinal implant designed to help correct and straighten spinal deformities in growing children, without the need for a brace or extensive future spinal fusion surgeries.

Biomedical Implant Technology Logo
Biomedical Implant Technology

Biomedical Implant Technology aims to provide dental implant training programs and a patented, one-piece, one-stage implant system.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.